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Background. Caffeine is widely used to treat apnea of prematurity. Here, we evaluated the efficacy of early caffeine (1-2 DOL)
in decreasing the incidence of adverse neonatal outcomes. Methods. A retrospective cohort was used to compare the neonatal
morbidity of 150 preterm neonates with gestational age ≤29 weeks. Infants were divided into 3 groups based on the initiation
timing of caffeine therapy; (1) early caffeine (1-2 DOL), (2) late caffeine (3–7 DOL), and (3) very late caffeine (≥8 DOL). Results.
The neonatal outcomes of early caffeine were comparable with those of the late caffeine group. Moreover, when comparing the
neonatal morbidity of the very late caffeine group with that of the early caffeine group, multivariable logistic regression analyses
were performed. We found that the timing of caffeine did not influence the risk of BPD (OR, 0.393; CI, 0.126–1.223; 𝑝 = 0.107),
but birthweight did (OR, 0.996; CI, 0.993–0.999; 𝑝 = 0.018) in these infants. Conclusion. Neonatal outcomes of preterm infants
were comparable whether caffeine was administered early or late in the first 7 DOL. The risk of BPD in infants receiving caffeine
after 8 DOL was irrespective of delayed treatment with caffeine. Our results clearly demonstrate the need for further studies before
caffeine prophylaxis can be universally recommended.

1. Introduction
Apnea of prematurity (AOP), defined as the cessation of
breathing for more than 20 seconds, is commonly seen in
preterm infants. Caffeine and other methylxanthines have
been used to treat AOP for the past 40 years [1, 2]. However,
the effectiveness and safety of caffeine therapy were first
investigated rigorously later on by the multicenter trial led
by Erenberg and colleagues as well as the international trial
on caffeine for apnea (CAP trial) [3, 4]. In the CAP trial,
infants with a birth weight of 500 to 1250 g, whose clinicians
considered treatment with caffeine during the first 10 days of
age, were randomly assigned to receive caffeine or placebo
treatment. This study suggested a beneficial effect of caffeine

on the incidence of bronchopulmonary dysplasia [4] as well
as improved neurodevelopmental outcomes at 21 months [5].
A subgroup analysis of this randomized trial has further
suggested early treatment with caffeine (≤3 days of life, DOL)
is associated with a reduction in ventilation times when
compared with infants with late caffeine treatment (4–10
DOL) [6].
Several studies have recently shown that early use of
caffeine in preterm neonates was associated with decreased
rates of death, bronchopulmonary dysplasia (BPD), and
symptomatic patent ductus arteriosus (PDA) in the absence
of adverse outcomes [7–10]. These studies, although well
conducted, may contain a bias in outcome measures, favoring the prognosis of preterm infants with early caffeine.
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Table 1: Characteristics of preterm infants in this study1 .

Variables
𝑁
Gestational age, wk
Birth weight, g
Sex (female/male)
Birth history (multiple birth)
Vaginal delivery
Chorioamnionitis
Apgar, 1 min
Apgar, 5 min
Surfactant
Ethnicity
African American and Hispanic Black

Early caffeine
(1-2 DOL)

Late caffeine
(3–7 DOL)

Very late
caffeine
(≥8 DOL)

85
26.34 ± 1.84
891.78 ± 227.50
38/47
(44.7%, 55.3%)
14 (16.5%)
46 (54.1%)
11 (12.9%)
5.41 ± 2.26
7.29 ± 1.45
67 (78.8%)

46
26.41 ± 1.80
909.13 ± 243.92
28/18
(60.9%, 39.1%)
8 (17.4%)
16 (34.8%)
8 (17.4%)
5.61 ± 2.10
7.31 ± 1.58
35 (76.1%)

19
25.94 ± 2.01
835.61 ± 188.70
9/10
(47.4%, 52.6%)
1 (5.3%)
8 (42.1%)
1 (5.3%)
5.11 ± 2.13
7.42 ± 1.17
15 (78.9%)

95%

95%

95%

p value

𝑝 = 0.15
𝑝 = 0.1
𝑝 = 0.27
𝑝 = 0.48
𝑝 = 0.41
𝑝 = 0.86
𝑝 = 0.58
𝑝 = 1.0
𝑝 = 0.77

1
This study includes preterm infants with GA = 23–29 weeks and BW < 1500 g.
DOL, days of life.

Preterm infants who were given caffeine demonstrated a
high likelihood of being weaned off mechanical ventilation
[11]. Clinicians administered caffeine shortly before planned
extubation to prevent apneic episodes. In contrast, preterm
infants with late caffeine were often associated with prolonged
mechanical ventilation and poor health and were remote
from extubation. Thus, the efficacy of early caffeine in
benefitting pulmonary and neurological outcomes remains
uncertain. Our hypothesis was that earlier administration of
caffeine is a marker of a healthier preterm infant who would
exhibit better neonatal outcomes. To test this hypothesis, this
study included (1) preterm infants with caffeine in 1-2 DOL
in the early caffeine group, (2) infants receiving caffeine in
3–7 DOL in the late caffeine group, and (3) infants receiving
caffeine after 1 week of life (≥8 DOL) in the very late caffeine
group. Moreover, the study included infants with gestational
age (GA) ≤ 29 weeks. Preterm infants with GA > 29 weeks
were excluded from this study since these infants have lower
chance to develop neonatal morbidity and therefore are more
appropriate to receive caffeine only after developing apnea
[11].

2. Methods
2.1. Patient Population. A retrospective study was conducted
on infants admitted to and treated in the Level III NICU of
Kings County Hospital with gestational ages of 23–29 weeks,
in the period from January 2010 to December 2014. Infants
with major congenital malformations and those who died
prior to discharge were excluded from this study. Preterm
infants were divided into three groups based on the initiation
timing of caffeine: the early caffeine group (1-2 DOL), the late
caffeine group (3–7 DOL), and the very late caffeine group
(≥8 DOL).
Clinical outcomes of preterm infants were assessed from
chart review. Infants were analyzed for gender, birthweight

(BW), and GA, as well as the maternal history which
included mode of delivery and birth history (single versus
multiple birth) (Table 1). The short-term outcomes which
were evaluated in this study are shown in Table 2, which
includes duration of NICU stay, bronchopulmonary dysplasia
(BPD), respiratory distress syndrome (RDS), retinopathy
of prematurity (ROP), and necrotizing enterocolitis (NEC).
BPD was defined as requiring supplemental O2 therapy
and/or respiratory support at postmenstrual age of 36 weeks
[8, 10]. Infants who were discharged before 36 weeks on room
air were defined as having no BPD. ROP was diagnosed by
a pediatric ophthalmologist as part of routine screening and
ROP was defined according to the international classification [12–14]. NEC was defined using Bell criteria [15]. The
diagnosis of RDS was based on the presence of tachypnea,
retractions or nasal flaring, grunting, central cyanosis, and
chest radiograph [16].
2.2. Statistical Analysis. Descriptive statistics including frequencies and counts were performed separately for the total
sample. Crosstabs and Fisher’s Exact Test (for cell sizes ≤ 5)
were used for comparisons of categorical variables between
early and late caffeine use. In the presence of multiple
variables such as GA and BW, a multiple logistic regression
was performed to assess the effects of caffeine timing on
neonatal outcomes. All analyses were done using SPSS v23
(IBM, WA).

3. Results
A retrospective study was performed on preterm infants
admitted to the NICU of Kings County Hospital from January
1, 2011, to December 31, 2014. This study population consisted
of predominantly African Americans and a small percentage
of other racial backgrounds. There were a total of 150 infants
≤29 weeks gestational age who met inclusion criteria for this
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Table 2: (a) Neonatal outcomes of infants receiving early caffeine (1-2 DOL) and late caffeine (3–7 DOL). (b) Neonatal outcomes of infants
receiving early caffeine (1-2 DOL) and very late caffeine (≥8 DOL). (c) Prediction of BPD and PDA ligation in infants with early caffeine (1-2
DOL) and very late caffeine (≥8 DOL) by multiple logistic regression analysis.
(a)

Early caffeine
(1-2 DOL)
𝑁
GA (wks)
BW (g)
Sex (female/male)
Duration of NICU stay
BPD
ROP requiring surgery
RDS
PDA
PDA requiring ligation
Necrotizing enterocolitis
PVL

Late caffeine
(3–7 DOL)

85
26.34 ± 1.84
891.78 ± 227.50
38/47 (44.7%, 55.3%)
Short-term clinical assessment
79.79 ± 30.51
23 (27.1%)
7 (8.2%)
65 (76.5%)
41 (48.2%)
4 (4.7%)
8 (9.4%)
4 (4.7%)

p value

46
26.41 ± 1.80
909.13 ± 243.92
28/18 (60.9%, 39.1%)

𝑝 = 0.53
𝑝 = 0.69
𝑝 = 0.10

76.73 ± 25.43
14 (30.4%)
0
36 (78.3%)
25 (54.3%)
3 (6.5%)
5 (20%)
0

𝑝 = 0.18
𝑝 = 0.69
𝑝 = 0.10
𝑝 = 1.00
𝑝 = 0.58
𝑝 = 0.70
𝑝 = 0.39
𝑝 = 0.30

DOL, days of life; BPD, bronchopulmonary dysplasia; ROP, retinopathy of prematurity; RDS, respiratory distress syndrome; PDA, patent ductus
arteriosus; PVL, periventricular leukomalacia.
(b)

Early caffeine
(1-2 DOL)
𝑁
GA (wks)
BW (g)
Sex (female/male)
Duration of NICU stay
BPD
ROP requiring surgery
RDS
PDA
PDA requiring ligation
Necrotizing enterocolitis
PVL

Very late caffeine
(≥8 DOL)

85
26.34 ± 1.84
891.78 ± 227.50
38/47 (44.7%, 55.3%)
Short-term clinical assessment
79.79 ± 30.51
23 (27.1%)
7 (8.2%)
65 (76.5%)
41 (48.2%)
4 (4.7%)
8 (9.4%)
4 (4.7%)

𝑝 value

19
25.94 ± 2.01
835.61 ± 188.70
9/10 (47.4%, 52.6%)

𝑝 = 0.01∗
𝑝 = 0.009∗
𝑝 = 0.35

77.13 ± 30.15
9 (47.4%)1
2 (10.5%)
15 (78.9%)
12 (63.2%)
2 (10.5%)2
0
0

𝑝 = 0.25
𝑝 = 0.047∗
𝑝 = 0.36
𝑝 = 0.74
𝑝 = 0.50
𝑝 = 0.04∗
𝑝 = 0.1
𝑝 = 1.0

(∗) means statistically significant.
1
These infants received caffeine on days 8, 9, 9, 14, 15, 16, 22, 27, and 53.
2
One infant received caffeine on day 19 and the other had caffeine on day 27.
DOL, days of life; BPD, bronchopulmonary dysplasia; ROP, retinopathy of prematurity; RDS, respiratory distress syndrome; PDA, patent ductus
arteriosus; PVL, periventricular leukomalacia.
(c)

Odds ratio
Initiation timing of caffeine therapy
GA (wks)
BW (g)

0.393
0.878
0.996

BPD
95% confidence interval
Lower
Upper
0.126
1.223
0.642
1.202
0.993
0.999

𝑝 value
0.107
0.416
0.018∗
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(c) Continued.

Odds ratio
Initiation timing of caffeine therapy
GA (wks)
BW (g)

0.473
0.842
0.997

PDA requiring ligation
95% confidence interval
Lower
Upper
0.075
2.967
0.467
1.518
0.991
1.004

𝑝 value
0.424
0.567
0.404

(∗) means statistically significant.
DOL, days of life; BPD, bronchopulmonary dysplasia; PDA, patent ductus arteriosus; GA, gestational week; BW, birthweight.

Table 3: Neonatal outcomes of infants receiving early caffeine (1-2 DOL) and all infants with caffeine ≥3 DOL.

𝑁
GA (wks)
BW (g)
Sex (female/male)

Early caffeine
(1-2 DOL)

Caffeine after day 3
(≥3 DOL)

85

65

26.34 ± 1.84

26.28 ± 1.89

𝑝 = 0.35

891.78 ± 227.50

888.08 ± 239.72

𝑝 = 0.73

38/47 (44.7%, 55.3%)

37/28 (56.9%, 43.1%)

𝑝 = 0.27

79.79 ± 30.51

75.72 ± 27.64

𝑝 = 0.47

23 (27.1%)

23 (35.1%)

𝑝 = 0.16

p value

Short-term clinical assessment
Duration of NICU stay
BPD

7 (8.2%)

2 (3.1%)

𝑝 = 0.10

RDS

65 (76.5%)

51 (78.5%)

𝑝 = 0.85

PDA

41 (48.2%)

37 (56.9%)

𝑝 = 0.61

ROP requiring surgery

PDA requiring ligation

4 (4.7%)

4 (6.2%)

𝑝 = 0.32

Necrotizing enterocolitis

8 (9.4%)

8 (12.3%)

𝑝 = 1.00

PVL

4 (4.7%)

2 (3.1%)

𝑝 = 0.27

DOL, days of life; BPD, bronchopulmonary dysplasia; ROP, retinopathy of prematurity; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus;
PVL, periventricular leukomalacia.

analysis. The participating infants were divided into 3 groups
based on the initiation timing of caffeine therapy and their
neonatal outcomes were compared. Of 150 preterm infants, 85
infants received early caffeine (1-2 DOL), 46 infants received
late caffeine (3–7 DOL), and 19 infants who received caffeine
after 1 week of life (≥8 DOL) were included in the very late
caffeine group. We did not observe any statistical difference
in the neonatal outcomes of infants between the early and
late caffeine group (i.e., 1-2 DOL and 3–7 DOL) (Table 2(a)),
suggesting that preterm infants exhibited comparable neonatal morbidity whether receiving caffeine early of late in the
first week of life. However, when we compared the outcomes
of early caffeine with that of the very late caffeine group (≥8
DOL), our analysis showed that this very late caffeine group
had higher incidence of BPD (47.4 versus 27.1%, 𝑝 = 0.047)
and PDA requiring ligation (10.5 versus 4.7%, 𝑝 = 0.04)
(Table 2(b)). We therefore examined the initiation timing of
caffeine therapy for each of these infants (footnotes, Table 2)
and found that a high percentage of these infants received
caffeine after 14 days of life (66.7% and 100%, resp.), associated with the fact that preterm infants in this group were
significantly more immature (25.94 wks versus 26.34 wks,
𝑝 = 0.01) and smaller (835 g versus 891 g, 𝑝 = 0.009). A

multiple logistic regression analysis was therefore performed
to incorporate these variables. We found that the timing of
caffeine treatment did not influence the risk of BPD (OR,
0.393; CI, 0.126–1.223; 𝑝 = 0.107) but the BW did (OR, 0.996;
CI, 0.993–0.999; 𝑝 = 0.018) in these infants (Table 2(c), top).
Moreover, the incidence of PDA requiring ligation was comparable between the early and the very late caffeine groups
(OR, 0.473; CI, 0.075–2.967; 𝑝 = 0.424) (Table 2(c), bottom).
As a comparison, we performed additional analyses using
similar criteria as previous reports [7–10]. Of the 150 infants,
85 were in the early caffeine group (1-2 DOL) and 65 infants
received caffeine later (≥3 DOL). In contrast to previous
reports, we did not observe any statistical difference in the
tested neonatal morbidities, including BPD, ROP, RDS, PDA,
and NEC between the early caffeine (1-2 DOL) and late
caffeine groups (≥3 DOL) (Table 3).

4. Discussion
This single center study had several unique features which
were designed to reevaluate the benefits of early caffeine on
neonatal outcomes compared to that of late caffeine therapy.
First, similar to previous reports [7–10], this study included
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infants with caffeine in the first 2 DOL in the early caffeine
group. The selection for the late caffeine group was more
stringent. Preterm infants with caffeine at 3–7 DOL were
included in the late caffeine group, whereas those receiving
caffeine after 1 week of life (≥8 DOL) were included in the very
late caffeine group. Our results demonstrated comparable
neonatal outcomes whether caffeine treatment was administered early or late within the first 7 DOL. In contrast, the early
caffeine group appeared to show a lower incidence of BPD
and PDA ligation only when compared with those receiving
caffeine very late (≥8 DOL). However, since the mean GA and
BW of this very late caffeine group were significantly lower,
we speculate that this difference was due to the immaturity
of these infants. Using multiple logistic regression to control
these variables, we found that the initiation timing of caffeine
was not associated with the risk of BPD. Moreover, there was
no statistical difference in the incidence of PDA requiring
ligation between the early and the very late caffeine groups.
This finding is consistent with current neonatal practice, in
which most infants start receiving caffeine treatment when
the clinician feels that they are able to be weaned from ventilator support. That is, the early caffeine group often included
healthier and more mature infants, whereas the late caffeine
group included infants who received caffeine very late due
to prolonged ventilation and greater immaturity. Together,
this study unveiled the importance in patient selection when
comparing the effects of early and late caffeine.
Several reports [7, 8, 10] have previously suggested greater
benefits of early caffeine (0–2 DOL) in preventing BPD,
lowering the incidence of PDA requiring ligation, decreasing
length of mechanical ventilation, and decreasing NICU
length of stay compared to caffeine treatment beyond this
period (i.e., all infants with caffeine ≥3 DOL). Using the same
grouping method, the mean GA and BW of both groups
in our study population were similar. However, we did not
observe any significant difference in neonatal outcomes of
preterm infants with early or late caffeine, including BPD,
ROP, and PMV (Table 3). This discrepancy may be due to
differences in patient selection as described above. Moreover,
we acknowledge that the small sample size in our study
may affect the statistical power to detect any difference
using this grouping method. The definition of BPD may also
contribute to this discrepancy. Here, we defined BPD using
the same criteria as two multicenter studies described [8, 10],
whereas the single center study by Patel et al. was based
on a web-based BPD estimator to predict the probability of
BPD [7]. Lastly, this study included a relatively homogenous
racial composition (>95% African Americans), whereas other
studies had a mixed population.
Together, this study applied more stringent criteria to
compare the neonatal outcomes of preterm infants with
respect to the timing of caffeine treatment. We divided infants
into 3 groups based on the initiation timing of caffeine: early
(<3 DOL), late (3–7 DOL), and very late (≥8 DOL). We found
that administering caffeine to preterm infants whether early
or late in the first 7 DOL was likely to have comparable effects
on neonatal morbidity. Moreover, the risk of BPD in the
very late group (≥8 DOL) was not associated with delayed
treatment with caffeine. Our results clearly demonstrate the
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need for a randomized controlled trial of early versus late
caffeine in infants below 29 weeks’ gestational age before early
caffeine prophylaxis can be universally recommended.
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